Table 1.
Characteristics of studies included in the meta-analysis
| Author | Year | Journal | Region | N total | Age mean (range) |
Tumor type | PD-1+ CTC |
Cutoff PD-L1+ CTC/mL |
CTC detection Method | PD-L1 antibody | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anantharaman | 2016 | BMC Cancer | America | 25 | 67(43–89) | Bladder cancer | 7 | 1 | EPIC Sciences Platform | CST | ||||||||||
| Boffa | 2017 | Cancer Epidemiol Biomarkers Prev |
America | 112 | 67.5(59–76.5) | NSCLC | 26 | 1.1 | EPIC Sciences Platform | CST | ||||||||||
| Cheng | 2020 | Cancer Management and Research |
China | 66 | 62(48–79) | NSCLC | 22 | 1% | HE pathological staining | Abcam | ||||||||||
| Dhar | 2018 | ScientIfic Reports | America | 22 | 69.4(51–91) | NSCLC | 7 | 2 | Vortex HT chip | ProSci Inc | ||||||||||
| Dong | 2019 | Front Oncol | China | 114 | 60.9 | NSCLC | 56 | - | CanPatrolTM | RNA-ISH | ||||||||||
| Guibert | 2018 | Lung Cancer | France | 96 | 60 (30–81) | NSCLC | 74 | 1% 5% 10% | ISET platform | CST | ||||||||||
| Ilie′ | 2018 | Annals of Oncology | France | 106 | 65 (41–86) | NSCLC | 71 | 1 | ISET platform | Ventana | ||||||||||
| Kallergi | 2018 | Therapeutic Advances In Medical Oncology |
Greece | 30 | - | NSCLC | 9 | 3 | ISET platform | Biolegend Novus Biologicals |
||||||||||
| Khattak | 2020 | The Oncologist | Australia | 40 | 71 | Melanoma | 14 | - | Flow Cytometric Staining | R&D System | ||||||||||
| Kulasinghe | 2018 | Cancer Medicine | Australia | 56 | 60 (21–82) | HNSCC NSCLC |
17 | - | ClearCell FX system | Abcam | ||||||||||
| Liu | 2020 | Molecular Oncology | China | 70 | 63 | Gastric cancer | 50 | 8 | Flow Cytometric Staining | CST | ||||||||||
| Papadaki | 2020 | Cancers | Greece | 198 | 60(29–84) | Breast cancer | 60 | 1 | - | CST | ||||||||||
| Satelli | 2016 | ScientIfic Reports | America | 92 | - | Colon cancer prostate cancer |
64 | 50% | Flow Cytometric Staining | Flow cytometry | ||||||||||
| Tada | 2020 | Oral Oncology | America | 44 | 66 | HNSCC | 11 | - | CellSieve™ microfilter | RT-qPCR | ||||||||||
| Yue | 2018 | Oncoimmunology | China | 35 | - | Gastrointestinal cancer |
26 | 2 20% | Pep@MNPs isolated system | KN802 | ||||||||||
| Adams | 2017 | Clinical Cancer Research | America | 41 | Lung cancer | 17 | 2 | CellSieve™ microfilter | R&D systems | |||||||||||
| Manjunath | 2019 | Cancers | America | 30 | 65(50–79) | NSCLC | 30 | 3 | CellSieve™ microfilter | CST | ||||||||||
| Strati | 2017 | Annals of Oncology | Greece | 113 | 65 | HNSCC | 24 | - | RosetteSep System | CellSearchTM analysis |
||||||||||
| Wang | 2019 | ScientIfic Reports | America | 38 | 67(57–89) | NSCLC | 25 | 5% | GO chip Immunofluorescence staining |
BioLegend | ||||||||||
| Zhang | 2020 | Cancer Letters | China | 16 | - | NSCLC | 7 | - | SE-iFISH | IF(-) | ||||||||||
Aberrations: NSLCC: Non-small cell lung carcinoma, HNSCC: Head and neck squamous cell carcinoma, PD-1: Programmed cell death-1, QA: Quality Assessment.